

Pharmx renews national NDSS agreement and delivers strong momentum on supplier growth

Pharmx Technologies (ASX:PHX) (Pharmx) is pleased to report significant progress against its FY25 strategic supplier objectives, including the renewal of its long-standing National Diabetes Services Scheme (NDSS) agreement and strong momentum in supplier growth across Australia and New Zealand.

Strategic NDSS Agreement Renewal

Pharmx is pleased to confirm the renewal of its long-standing agreement with the National Diabetes Services Scheme (NDSS), with a 12-month extension to the existing arrangement commencing 1 July, 2025. This renewal reflects the continued confidence of key health stakeholders in the Pharmx platform and underscores its role as essential digital infrastructure within Australia's healthcare supply chain.

NDSS ordering remains one of the most frequent and operationally embedded digital workflows in Australian pharmacies. Its continued integration with the Pharmx network affirms the platform's relevance to core pharmacy operations and national health service delivery.

The continuation of this agreement reaffirms Pharmx's commitment to national health service delivery and strengthens its position as an enabler of pharmacy operations at scale.

Supplier Network Expansion Strengthens Platform Value

As part of its FY25 focus on expanding Supplier Growth, Pharmx has secured partnerships with over 50 new suppliers across Australia and New Zealand – bringing the total number of active suppliers on the Pharmx platform to more than 170.

This momentum reflects Pharmx's strategic objective to enhance platform utility, improve pharmacy engagement, and sustain commercial performance. Notable new supplier partners include:

- Homart (AU)
- Healthylife (AU)

- Edgewell (NZ)
- Solgar (NZ)

These suppliers bring high-demand, category-leading products to the platform, enhancing pharmacy access to essential stock while driving increased transaction volume and order frequency across the Pharmx network. Pharmx's disciplined and targeted approach to supplier acquisition delivers value to both pharmacies and their customers through broader product availability, operational efficiency, and streamlined digital ordering.

Through the renewal of a key national health partnership and the ongoing expansion of its supplier base, Pharmx continues to strengthen its leadership as the region's most connected pharmacy ordering network.

Pharmx looks forward to sharing a broader update on FY25 progress in its upcoming end-of-year reporting.

ENDS

This announcement has been authorised for lodgement by the Chairman.

For further information contact:

Tom Culver
Chief Executive Officer
investor.relations@pharmx.com.au

About Pharmx Technologies Ltd.

Pharmx is ANZ's leading pharmacy ordering platform, providing essential technology infrastructure for seamless ordering and inventory management. By connecting the largest network of pharmacies, suppliers, and technology vendors, Pharmx facilitates approximately \$20 billion in transactions annually through its robust, high-availability platform – driving efficient operations, seamless connectivity, and valuable insights across its ordering, invoicing, and analytics solutions.

Operating in a dynamic and evolving market, Pharmx is positioned for sustained growth, driven by population growth, demographic shifts, and regulatory changes. With a strategic focus on expanding its addressable market, Pharmx leverages its extensive network, proprietary pharma-tech, and advanced data capabilities to unlock new revenue opportunities and enhance healthcare outcomes across Australia and New Zealand.